Biosimilar vs Generic Drug: Critical Differences Every Biopharma Professional Should Know
Deciphering the Biosimilar vs Generic Drug Differences in Modern Biopharma The biopharmaceutical industry has entered a transformative era in which […]
Extractables and Leachables in Dexamethasone Injectables
Introduction: Extractables and leachables in dexamethasone injectables represent one of the most critical — yet often underestimated — challenges in
Extractables and Leachables in Dexamethasone Injectables Read More »
Case Study: Bioanalytical Method Development for a First-in-Class mRNA Therapeutic with Complex Matrix Challenges
Introduction: Bioanalytical method development for mRNA therapeutics is fundamentally different from conventional drug modalities — and getting it wrong at
Impurity Profiles and Their Role in Active Ingredient Sameness
Introduction: Impurity profiles in active ingredient sameness determinations are not a regulatory formality — they are a scientific proof of
Impurity Profiles and Their Role in Active Ingredient Sameness Read More »
GMP Manufacturing of Peptide-Oligonucleotide Conjugates: What to Expect from a CRO
Introduction: GMP manufacturing of peptide-oligonucleotide conjugates sits at the intersection of two highly complex chemistries — and getting it right
GMP Manufacturing of Peptide-Oligonucleotide Conjugates: What to Expect from a CRO Read More »
What Documents and Specifications to Provide When Outsourcing Peptide Characterization to a CRO
Introduction: When you decide to outsource peptide characterization, the quality of your results depends less on which CRO you choose
PLA Stereochemistry: PLLA vs PDLA vs PDLLA and Their Impact on Drug Delivery Performance
Introduction: PLA stereochemistry — specifically the ratio and arrangement of L- and D-lactic acid units — determines crystallinity, degradation rate,
PLA Stereochemistry: PLLA vs PDLA vs PDLLA and Their Impact on Drug Delivery Performance Read More »
What Makes a Peptide Drug Different from a Small Molecule? Analytical and Regulatory Implications
The modern pharmaceutical landscape is experiencing a significant transformation, moving beyond traditional low-molecular-weight compounds toward larger and more structurally sophisticated
PLGA, PLA, and PCL for IND-Enabling Studies: What to Source and When
Procurement Strategies for PLGA, PLA, PCL, and IND-Enabling Studies Supply Sourcing biodegradable polymers for IND-enabling studies requires the selection of
PLGA, PLA, and PCL for IND-Enabling Studies: What to Source and When Read More »
When Should You Start Nitrosamine Risk Assessment in Your Drug Development Program?
Introduction A formal nitrosamine risk assessment should begin during the preclinical stage of development, specifically during candidate selection and the
When Should You Start Nitrosamine Risk Assessment in Your Drug Development Program? Read More »